Celonic and IBI-Lorenzini announce a strategic collaboration

06-Sep-2016 - Switzerland

IBI-Lorenzini has entered into a partnership with the Swiss contract development and manufacturing organisation,Celonic, to establish high performance cell lines for R&D.

Cell line development is one of the most challenging phases, especially when subsequent GMP compliance is required. To boost and support successful commercial introduction of biological drugs to the market, Celonic has developed CHOvolution™, a cell line kit that can be used for a broad range of applications, ranging from non-GMP R&D testing to GMP development and commercial market supply – with a technical and scientific support system to help with every step.

“This agreement is a major step for IBI-Lorenzini. This partnership will strengthen the capabilities of our Biotech Department in the very early phases of the manufacturing process, and will allow us to offer a full service to clients wanting to enter quickly into the clinical phase”, commented Camilla Khevenhueller Borghese, President at IBI-Lorenzini.

Konstantin Matentzoglu, CEO at Celonic AG, added: “I am excited about this truly strategic partnership leveraging an innovative cell line development platform. Together, Celonic and IBI-Lorenzini will provide a safe and proven development platform to clients worldwide.”

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances